GO Therapeutics

Executive Summary

GO Therapeutics is a private biotechnology company headquartered in Cambridge, MA, focused on discovering and developing novel, highly selective cancer targets termed “super-clean” and corresponding antibodies. The company’s core innovation lies in identifying tumor-exclusive antigens expressed across a broad spectrum of solid cancers, thereby addressing the critical limitation of on-target, off-tumor toxicity that plagues current advanced therapies. By enabling highly precise targeting, GO Therapeutics aims to unlock the full potential of next-generation modalities including T-cell bispecifics, antibody-drug conjugates (ADCs), and CAR-T cells. Founded in 2017, the company operates in the preclinical stage and has not publicly disclosed its pipeline or financing details, but its platform approach holds promise for safer and more effective solid tumor treatments.

Upcoming Catalysts (preview)

• Q3 2026IND filing for lead candidate50% success
• Q3 2026Initial preclinical efficacy data presentation70% success
• Q4 2026Strategic partnership or licensing deal40% success